PubMed Health⌕ Search

Biomedical subjects

A W Forrey

Publications and source records attributed to A W Forrey.

At least 19 recordsLinked to original sources
PubMed1996

Logical observation identifier names and codes (LOINC) database: a public use set of codes and names for electronic reporting of clinical laboratory test results.

Many laboratories use electronic message standards to transmit results to their clients. If all laboratories used the same "universal" set of test identifiers, electronic transmission of results would be greatly simplified. The Logical Observation Identifier Names and Codes (LOINC) database aims to be such a code system, covering at least 98% of the average laboratory's tests. The LOINC database should be of interest to hospitals, clinical laboratories, doctors' offices, state health departments, governmental healthcare providers, third-party payors, organizations involved in clinical trials, and quality assurance and utilization reviewers. The fifth release of the LOINC database, containing codes, names, and synonyms for approximately 6300 test observations, is now available on the Internet for public use. Here we describe the LOINC database, the methods used to produce it, and how it may be obtained.

Clinical Laboratory Information Systems↗
PubMed1987

Medical nomenclature and common conventions for trauma registries.

A trauma registry has been created containing lexicons of terms arranged to foster the adoption of standardized and extensible terminology for the nature and mode of injury. Identification of attribute sets for the nature-of-injury (body region:detailed part:type of injury) and for the mode-of-injury (mechanism:agent:activity:intent:setting) allows the assembly of a clear, concise, easily usable, nad extensible format for representing the appropriate level of detail for nomenclature or classification. This ability allows the use of a common list of terms that is adaptable for case records used in patient care as well as in trauma registry statistics. Several examples of reports using these attributes are shown.

Humans↗
PubMed1980

Human factor IX in animals: kinetics from isolated, radiolabelled protein and platelet destruction following crude concentrate infusions.

Crude, concentrated and isolated, labelled human factor IX was prepared and infused into animals. Initially, two dogs with severe haemophilia B received both preparations and factor IX clotting activity and label survived well. Kinetic parameters fit a two-compartment open model. For 12 infusions of concentrates into normal baboons, clotting and antigen data again fit the model. Similar kinetics, with less variability, were found for nine infusions of [125I]factor IX. Radioactivity of the first post-infusion samples was > 90% precipitated in the double antibody system with an average of 84% of counts adsorbable to barium citrate. Compared to plasma, barium adsorbable counts gave a shorter t1/2 beta-elimination phase suggesting a small recirculating 125iodide pool. When [125I]factor IX was rechromatographed over heparin-agarose, variable amounts of altered, labelled protein were present; this species was more rapidly cleared from plasma post-infusion. Twelve infusions of crude concentrates into baboons were given to animals whose platelets had been labelled with 51Cr. Platelet counts as well as survival were then followed. For seven of these animals, mean counts decreased and the labelled platelets were destroyed, to an average of 21%, during the first 4 h post-infusion. Subsequent platelet survival was normal. Three infusions of gel-filtered, crude concentrates and two infusions of 'activated' commercial concentrates did not significantly alter platelet survival.

Animals↗
PubMed1976

Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay.

The acetylating radioenzymatic assay was used for determination of levels of amikacin in serum and urine. Because of an inhibitor present in various amounts in urine, assay of amikacin in urine by this method requires added internal standards and thus is less precise than the assay in serum. Determination of the rate of plasma clearance, half-life, and volume of distribution of amikacin in 10 patients with normal renal function, four patients undergoing dialysis, and five patients with end-stage renal diseases have shown a relation of half-life (t1/2 in hr) to rate of clearance of serum creatinine (Cer) of t1/2 = 3 X Cer, the same relation as found for kanamycin and gentamicin. The apparent steady-state volume of distribution of amikacin in patients with diminished renal function is slightly, but not significantly, larger than that in normal patients; the values were 0.28 +/- 0.10 and 0.21 +/- 0.10, respectively. In normal patients, 87% of the drug is excreted by the kidney.

Acetylation↗
PubMed1975

Assay of flucytosine and furosemide by high-pressure liquid chromatography.

A high-pressure liquid chromatographic method for the analysis of flucytosine and furosemide concentrations in biological fluid is described. The separations were carried out on a pellicular cation-exchange resin eluted with an ammonium phosphate buffer. Detection of elution peaks was by UV absorption at 280 nm and fluorescence monitoring. Advantages of the method are specificity, minimal preanalysis sample workup, and small sample size.

Buffers↗